Cardarine

Cardarine, designated GW-501516, is a synthetic peroxisome proliferator-activated receptor delta (PPARd) agonist originally developed by GlaxoSmithKline and Ligand Pharmaceuticals in the 1990s. It is not a SARM — it does not bind the androgen receptor or exert any hormonal activity. GW-501516 is a metabolic modulator that targets nuclear receptor pathways governing fatty acid oxidation, mitochondrial biogenesis, and endurance capacity. It is categorized alongside SARMs due to its widespread use in performance research and its complementary metabolic effects.

GW-501516 activates PPARdelta, a nuclear receptor expressed ubiquitously in skeletal muscle, adipose tissue, and liver. Upon activation, PPARd upregulates the transcription of genes involved in fatty acid beta-oxidation (CPT1, ACOX1), mitochondrial uncoupling (UCP3), and oxidative phosphorylation — effectively reprogramming cellular energy metabolism from glycolytic (sugar-burning) to oxidative (fat-burning). In landmark preclinical research published in Cell, GW-501516 administration in sedentary mice increased running endurance by 68% and running distance by 70%, independent of exercise training. It essentially mimics the metabolic adaptations of endurance exercise at the gene expression level.

The research literature positions GW-501516 as the most potent endurance-enhancing compound available. Its effects include dramatic increases in cardiovascular exercise capacity, accelerated fat oxidation during both exercise and rest, reduction of circulating triglycerides and LDL cholesterol, improvement of insulin sensitivity, and preservation of lean mass during caloric deficit. The compound gained notoriety when WADA banned it in 2009, issuing a rare pre-emptive alert to athletes regarding GW-501516's performance-enhancing effects even before it completed clinical development.

Cardarine is appropriate for researchers at any experience level, particularly those focused on endurance performance, cardiovascular metabolic health, and fat loss. Because it has no androgenic activity, it stacks seamlessly with any SARM, anabolic compound, or peptide without interaction concerns. It is a foundational component of cutting stacks, where it accelerates fat oxidation while preserving lean tissue. Common pairings include Ostarine + Cardarine for cutting, or RAD-140 + Cardarine for lean recomposition.

GW-501516 has an elimination half-life of 16–24 hours, supporting once-daily oral dosing. Oral bioavailability is excellent. There is zero testosterone suppression and no PCT requirement. The compound produces no hepatotoxicity, no estrogenic effects, and no significant adverse effects at standard research doses. The primary safety consideration in the literature involves preclinical rodent carcinogenicity findings at doses far exceeding typical research protocols (orders of magnitude higher, for durations equivalent to years of human use). Standard research protocols range from 10–20mg daily for 8–12 weeks.